MODERN DISEASE PREVENTION
Your Subtitle text

Physicians pour drugs of which they know little to cure diseases of which they know less, into humans of whom they know nothing. 
Voltaire (François-Marie Arouet) 
 

The limbic system is the collective name for structures in the human brain involved in emotion, motivation, and emotional association with memory. Shown to play a key role in the processing of emotions, the amygdala forms part of the limbic system. The amygdala is an almond-shape set of neurons located deep in the brain's medial temporal lobe. In humans and other animals, this subcortical brain structure is linked to both fear responses and pleasure. Its size is positively correlated with aggressive behavior across species. In humans, it is the most sexually-dimorphic brain structure, and shrinks by more than 30% in males upon castration. Conditions such as anxiety, autism, depression, post-traumatic stress disorder, and phobias are suspected of being linked to abnormal functioning of the amygdala, owing to damage, developmental problems, or neurotransmitter imbalance.

FACE TO FACE
WITH THE EMOTIONAL BRAIN

by Ahmad R. Hariri & Paul J. Whalen
     Amygdala responses to the facial signals of others predict both normal and abnormal emotional states. An understanding of the brain chemistry underlying these responses will lead to new strategies for treating and predicting psychopathology.
     One of our favorite scientific studies of the past few years is a laboratory assessment of how people react to strangers. The research was conducted by Alex Todorov and colleagues at Princeton. They presented subjects with pictures of faces—many faces—that they had never seen before. All of the faces were intended to have no discernible expression, that is, they wore neutral expressions. The subjects were asked to rate how trustworthy they thought each face was based on a gut reaction. Naturally, each subject thought that some of the faces were more trustworthy-looking, some were less trustworthy-looking, and some were neutral. At the same time, the response of each subject’s amygdala—a deep brain structure—was measured using functional magnetic resonance imaging (fMRI).
     The measured responses showed some relationship with the judgments the subjects made about the faces. Specifically, the amygdala responses were greatest to faces judged to be the most untrustworthy. As cool as that is, it was not the most interesting finding.
     From the many and varied opinions of the individuals ranking the faces of strangers, Todorov and colleagues computed a mean trustworthiness rating for each face. The faces were then ordered in terms of what the group thought. This was a group rule; no one individual who was studied could possibly have known what this rule was. Yet, remarkably, the mean response of the amygdala across all subjects was positively correlated with the mean trustworthy ratings for the group of subjects. This extraordinary finding tells us that there may be fundamental rules by which our emotional brains process information and generate responses. These responses are initiated without our awareness or permission and they can form the basis of our biases and prejudices. This finding also fits well with previous data showing that the amygdala reacts to changes in subtle facial signals such as pupil dilation, and facial expression, even when subjects were not aware that these signals had occurred.
     The word “explicit” is used to define situations when we can put our experiences into words because we are aware of their occurrence. “Implicit” describes those things we do more automatically, that is, without monitoring them on a moment-to-moment basis such as motor skills like riding a bike or driving your car. We take it as a given that we have an automatic motor life. Is it then so radical to think about an automatic emotional life? Some of our immediate emotional impulses—say, in the first half second—are not entirely under our explicit control; they are implicit. Where in the brain does all this take place? While the interconnected nature of our brains makes it difficult to discern the exact networks that form the substrate of these implicit and explicit reactions, one structure that is clearly implicated is the amygdala, a highly conserved brain region buried in the temporal lobes. The amygdala is intimately involved in our implicit as well as explicit responses to emotional challenges we encounter in our environment.
     In the experiment described above, implicit cues about certain facial features appear to be tracked by the amygdala. These signals have an impact on our initial “gut” reactions concerning the relative trustworthiness of strangers. The good news from this is that you can forgive yourself your initial reactions. But then the important work begins, when you must efficiently invoke an explicit strategy to take control and produce behavior that is appropriate to the social moment.
     Automatic emotional responses make sense. We are under a constant barrage of sensory information from our external and internal worlds, which must be appropriately filtered and parsed into adaptive behaviors and physiological responses. It has been known for some time that the amygdala is critical for learning about environmental predictors of threat. Whether it is a rat in a cage learning that the tone it is hearing predicts something bad—for example, a mild shock to its feet—or a human being realizing that someone is coming up from behind them because the person in front of them just widened their eyes, it is the amygdala that monitors the environment for this particular tone or the widened eyes of a friend.
     While you might have been told that it is the “fight or flight” center of your brain, we think that it is better to think of the amygdala as one of the brain areas critical for learning about and then detecting these predictive environmental signals. The decision to fight or flee is likely made by other more complex brain systems after the amygdala has indicated that a predictive signal has been detected. That said—the amygdala does control some very initial and automatic reactions to threat. Examples include heart rate and respiration changes as well as somatomotor (movement-related) responses such as orienting and freezing in place. Freezing in the initial seconds of an emotional situation is sometimes a very good strategy and one that is invoked by rats and humans alike. If you don’t yet know whether to step left or right, better to stay put and learn a little more about your current predicament.
     Over the past decade, remarkable progress has been made in understanding the specific qualities of incoming stimuli or signals, especially those related to our social worlds that are filtered by the amygdala.
     As we have noted above, in humans the amygdala takes special note of the facial reactions of others in order to predict what will happen next. In the laboratory we directly study amygdala responses to signals of threat and safety by presenting subjects with photographs of facial expressions. Numerous laboratories have independently employed this strategy and all have shown that facial expressions, especially the expression of fear, are potent activators of the human amygdala. From the expressions of others we can glean information about their internal emotional state, their intentions, and their reaction to contextual events in the immediate environment. Facial expressions of emotion have predicted important events for us in the past, and in a brain scanner we can document some very similar responses to certain facial expressions based on these previous experiences. In this way, facial expressions are naturally conditioned stimuli.
     If the amygdala is constantly monitoring something as subtle as changes in the facial expressions of others, then it can play a pivotal role in the individual differences we see in how reactive some people are to the social signals of others compared to their peers. Implications of this for healthy interpersonal interactions are enormous. For example, if amygdala reactions were overly sensitive to the facial reactions of others, one might take a simple facial movement of a friend, one that was not intended to convey disapproval, as a certain slight.
     Aberrant amygdala reactions could play a part in exacerbating a host of psychopathologies. Indeed, numerous studies have identified abnormal amygdala responses to facial expressions across a variety of psychopathologies involving emotional dysfunction such as major depression, anxiety disorders, phobias, bipolar disorder, schizophrenia, and autism. More importantly, amygdala responses to facial expressions have been used to predict treatment outcomes in both depression and generalized anxiety disorder with lower pretreatment levels of amygdala response predicting better treatment outcomes.
Ahmad R. Hariri is Professor of Psychology and Neuroscience at Duke University and Paul J. Whalen is Associate Professor in the Department of Psychological and Brain Sciences at Dartmouth College.

BAD SCIENCE AND GOOD PUBLIC RELATIONS CREATED BIPOLAR DISORDER
     In less than a decade, from roughly 1994 to 2003, the diagnosis and treatment of bipolar disorder in children and adolescents underwent a dramatic and unwarranted increase. Before 1995 bipolar disorder was rarely diagnosed in children and adolescents; today the diagnosis is commonplace, with a forty-fold increase in the number of outpatient visits for this diagnosis in childhood. In 1995 there were 20,000 such visits; by 2003 the yearly number was 800,000! Now, nearly one-third of all children and adolescents discharged from child psychiatric hospitals have been diagnosed with bipolar disorder. Most of these diagnoses are incorrect.
     “Your Child Does Not Have Bipolar Disorder: How Bad Science and Good Public Relations Created the Diagnosis” examines this diagnostic fad through a variety of lenses. Author, Stuart L. Kaplan, MD., draws heavily on his forty years of experience as a clinician, researcher, and professor of child psychiatry, to make the argument that bipolar disorder in children and adolescents is incorrectly diagnosed and incorrectly treated.
     In this provocative book, child psychiatrist Stuart Kaplan offers a challenge to parents, mental health professionals, the drug industry, the research community, and the general public. He asserts that the soaring incidence of bipolar disorder diagnoses among children and adolescents is based on incorrect, newly created definitions of the disorder, and he marshals the evidence to back up his claim.
     Chronicling the enormous growth of bipolar diagnosis in children since 1995, Dr. Kaplan vigorously disputes the clinical and scientific bases (the "bad science") behind the diagnoses and explains the catastrophic clinical consequences. At the same time, he exposes the social and cultural dynamics that underlie this clinical fad. Dr. Kaplan discusses medications used to treat bipolar disorder and the biases that currently undermine their assessment. He concludes with specific advice for parents about managing symptoms commonly mistaken as bipolar disorder.
     As Dr. Stuart L. Kaplan explains, the dramatic rise in this particular diagnosis is not based on scientific evidence; it does not reflect any new discovery or insight about the etiology or treatment of the disorder. In fact, the opposite is the case: the scientific evidence against the existence of child bipolar disorder is so strong that it is difficult to imagine how it has gained the endorsement of anyone in the scientific community.
     In his just published book, “Your Child Does Not Have Bipolar Disorder: How Bad Science and Good Public Relations Created the Diagnosis”, Dr. Stuart Kaplan explains to parents and professionals the faulty reasoning and bad science behind the misdiagnosis of childhood bipolar disorder. He critiques the National Institute of Mental Health, academic child psychiatry, the pharmaceutical industry, and the media for their respective roles in advocating for the adoption of this diagnosis. Dr. Kaplan describes very clearly what the children and adolescents actually do have, and how it should be treated. He provides real-life clinical scenarios and describes approaches to treatment that work.
     Stuart L. Kaplan, MD has authored over 100 scientific papers, book chapters, abstracts and national and international scientific presentations. Dr. Kaplan graduated from George Washington University School of Medicine and Health Sciences (Washington, DC) in 1965, and interned at Jewish Hospital (Brooklyn, NY). He is Board Certified in Child Psychiatry and Adult Psychiatry by the American Board of Psychiatry and Neurology (ABPN) and served as an examiner for the American Board of Psychiatry and Neurology 14 times.
     Dr. Kaplan was Director of Child and Adolescent Psychiatry at the Long Island Jewish Hillside Medical Center, Executive Director of Rockland Children’s Psychiatric Center, Director of Child and Adolescent Psychiatry at Saint Louis University, Director of Child and Adolescent Psychiatry and Director of Child Psychiatry residency training at Penn State College of Medicine. Dr. Kaplan is Clinical Professor of Psychiatry at Penn State College of Medicine and also sees patients (Child Psychiatry).
Kaplan, Stuart L., MD. Your Child Does Not Have Bipolar Disorder: How Bad Science and Good Public Relations Created the Diagnosis. Greenwood Publishing Group. March 2011.


THE MARKETING OF MADNESS: The Truth About Psychotropic Drugs — Full Length Documentary



Disclaimer: Views expressed in articles or videos on this website do not necessarily reflect those of ModernDiseasePrevention, the owner, or its staff.
EFFICACY OF NUTRITIONAL AND HERBAL SUPPLEMENTS ON ANXIETY
     Anxiety disorders are one of many common psychological ailments. Natural remedies have been used for centuries in many cultures to alleviate anxiety and its symptoms with surprising effectiveness. In Western cultures, however, research that proves the usefulness of medicinal herbs and natural substances has only begun to gain momentum over the past few decades. In addition, the absence of proper guidelines governing the production and use of vitamins, minerals, amino acids and herbs for medicinal purposes is also causing the clinical prescription of these natural treatments to lag behind in the United States.
     With the lifetime prevalence of anxiety disorders reaching 16.6% worldwide, great strides have been made with ongoing research into its causes and treatments. In addition to antidepressants, serotonin-specific reuptake inhibitors (SSRIs) and benzodiazepines have also been prescribed to patients suffering generalized from anxiety disorder (GAD). However, while often effective, both of these classes of drugs come with many unwanted side effects such as suicidal ideation, decreased alertness, sexual dysfunction and dependency. Additionally, the costs of these medications pose problems to patients who must take them on a daily, long-term basis.
     As a result, there has been increased interest in the use of complementary and alternative medicines (CAM) as a natural method for treating numerous types of anxiety. Herbs such as passionflower, kava, St. John's wort and valerian root, as well as the amino acid lysine and the cation magnesium, have been used for centuries in folk and traditional medicine to calm the mind and positively enhance mood.
     Thus far, cognitive behavioral therapy (CBT) has proven to be the most effective, long-term treatment for anxiety-related disorders. However, the efficacy and safety of utilizing complementary and alternative medicines to treat anxiety, both as a symptom and as a disorder, has only just begun to be rigorously tested in clinical trials within the last 10 to 15 years.
     A number of reviews of the clinical effectiveness of herbal and nutrient treatments for depression, anxiety disorders, and sleep disturbance have been published over the past decade. These have reviewed data associated with a number of treatments, including St. John's wort, S-adenosyl-methionine (SAM-e), B vitamins, inositol, choline, kava, omega-3 fatty acids/fish extracts, valerian, lavender, melatonin, passionflower, skullcap, hops, lemon balm, black cohosh, ginkgo biloba, extracts of magnolia and phellondendron bark, gamma-aminobutyric acid (GABA), theanine, tryptophan and 5-hydroxytryptophan (5-HTP). However, none of these studies has been conducted in a systematic way.
     We restricted the search to herbs and supplements that acted as anxiolytic agents and whose effects were measured either through quantitative rating scales or self-reports. Studies also had to be published in English, conducted with human subjects, have a sample size greater than 10, use a whole extract of the plant (if applicable) and detail data clearly. Of the randomized controlled trials reviewed in this report, 71% (15 out of 21) showed a positive direction of evidence, and any reported side effects were mild to moderate.
     Based on this data, it appears that nutritional and herbal supplements are effective methods for treating anxiety and anxiety-related conditions without the risk of serious side effects. However, the effectiveness of each of the reviewed combinations and monotherapies has not been substantiated to the same degree.
     Passionflower has been studied in three different randomized controlled trials, twice as a monotherapy and once as part of an herbal combination. All three of these studies showed a positive benefit for treatment with passionflower, providing good evidence of its effectiveness as an anxiolytic agent. However, since each of these studies was conducted in a different patient type, more research is needed to prove its efficacy in each indication.
     Kava is the most researched supplement in this review with 11 different studies (10 RCTs and one observational). Of the randomized controlled trials of kava monotherapy, 63% (5/8) showed treatment significantly reduced anxiety symptoms in a variety of patient types. This provides good evidence for the use of kava in patients with generalized anxiety disorder, non-psychotic anxiety and other anxiety-related disorders.
     The evidence for St John's wort was mixed, with 50% (3/6) of the studies having positive results. However, the fact that only 1 out of the 4 randomized controlled trials had a positive direction of evidence and that the active treatment in this trial was a combination of St John's wort and valerian suggests that St John's wort monotherapy should not be recommended to patients suffering from anxiety disorders or other anxiety-related conditions.
     For all three of the reviewed herbal supplements, more research needs to be done to establish the most effective dosage and to determine whether this varies between different types of anxiety or anxiety-related disorders. Furthermore, as 3 of the 4 herbal combinations showed positive results, future research should focus on determining whether herbal combinations are similarly or more effective than monotherapy as well as refining the type of herbs and dosages contained in combination supplements.
     Combination nutritional supplements containing lysine or magnesium also appear to hold promise as treatments for anxiety symptoms and disorders. Both randomized controlled trials of L-lysine and L-arginine combinations demonstrated positive results, providing good but limited evidence of its usefulness as a treatment for anxiety. The evidence for magnesium is mixed. Even though all three randomized controlled trials of magnesium-containing supplements had positive results, magnesium monotherapy was shown to be no different than placebo, raising the question of whether magnesium provides any anxiolytic benefits in combination or whether the results were based on the actions of the other nutrients/herbal extracts.
     However, this study was conducted in women with premenstrual anxiety rather than an anxiety disorder. Future research should focus on elucidating magnesium's mode of action in order to determine if it has anxiolytic properties and provides any synergistic effects when combined with other natural anxiolytic agents. Herbal medicines hold an important place in the history of medicine, as most of our current remedies, and the majority of those to be discovered in the future will contain phytochemicals derived from plants.
     While locating the active ingredients in herbal substances is pivotal to being able to produce effective supplements, understanding the quantity needed and potency of different ways of extracting and preparing the phytochemicals is vital to creating a standard measure of their effectiveness. In addition, the dangers of overconsumption and interactions with prescription medications and over-the-counter medications need to be further analyzed. This understanding of the standards for effective preparation further minimizes the chance of side effects from herbal medicines and helps to create an undisputable body of evidence for their effectiveness.
Lakhan, Shaheen E; Vieira, Karen F. Nutritional And Herbal Supplements For Anxiety And Anxiety-Related Disorders: Systematic Review. Nutrition Journal 2010, 9:42. 07 Oct 2010. The electronic version of this article is the complete one and can be found online at:
http://www.nutritionj.com/content/9/1/42
 
Pamela Hyde, JD, is Administrator of the Substance Abuse and Mental Health Administration (SAMHSA). SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.
 
DEPRESSION:
EXAMINING THE SEX/ GENDER DIFFERENCES AND LINKS TO OTHER DISEASES
     Depression is not only a significant public health concern; it is also linked to many other prevalent diseases. The interaction of depression with other diseases was discussed at a Women's Health Seminar Series broadcast in September 2009, Sex and Gender Research: the Interaction of Depression with Other Diseases. The seminar was presented by the National Institutes of Health Office of Research on Women's Health. Several current and former NIMH grantees participated in the discussions.
    NIMH grantee Jill Goldstein, PhD., discussed sex differences that are pervasive in depression. Professor Goldstein is a Professor of Psychiatry and Medicine, Departments of Psychiatry and Medicine at Harvard Medical School. She stated that because depression is seen more frequently in females, trying to understand these differences will help clinicians tailor sex specific treatments. "The higher incidence of major depressive disorder in women is initiated during sexual differentiation in the brain. Fetal development, puberty, pregnancy, and menopause are all windows of opportunity in which to study the differences seen clinically in rates of major depression and mood disorder," explained Dr. Goldstein.
     Additionally, Dr. Jill Goldstein stated that there is a similarity of developmental risk factors during the second and third trimesters of pregnancy for depression and cardiovascular disease. These factors include: small gestational age, low birth weight, preeclampsia, and prenatal exposure of the mother to famine. "Sex differences exist in every tissue of the body" said Dr. Goldstein. "Disruption in the amygdala, hippocampus, hypothalamus, and white matter lead to the sex differences seen in depression, mood disorders, endocrine dysfunction, and heart rate." Professor Goldstein is Director of Research with Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital (BWH, "The Brigham"). It is directly adjacent to Harvard Medical School and The Brigham is the largest hospital of the Longwood Medical and Academic Area in Boston, Massachusetts.
     Although its relationship to depression is still largely unrecognized, another major public health problem costing billions of health care dollars and affecting millions of individuals each year is Osteoporosis. NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) investigator and former NIMH collaborator Giovanni Cizza, MD., PhD., M.H.Sc. presented data at the ORWH (Office of Research on Women's Health) Women's Health Seminar showing that chronic stress and depression result in significant bone loss, particularly in the hip. "We found that one in five premenopausal women with major depressive disorder exhibited low bone mineral density in the hip area. Depressed premenopausal patients exhibited the equivalent of one year of bone loss seen in post-menopausal patients," said Dr. Giovanni Cizza.
     Cancer is another health concern in which depression can play a role in the course of treatment. While ten to thirty percent of people with cancer are found to be depressed, the rates of depression vary with the age of onset of cancer, the type of cancer, and stage of treatment. Dr. Mary Jane Massie, attending psychiatrist at Memorial Sloan-Kettering Cancer Center and Professor of Clinical Psychiatry at the Weill Medical college of Cornell University presented data showing that at diagnosis, a third of patients said they were depressed. Fifteen percent said they were depressed at one year after diagnosis; and forty-five percent after recurrence. Dr. Mary Jane Massie explained "In my practice, very young cancer patients suffer from major depression as do those with more pain, specific types of chemotherapy, poor support systems, less optimism, low self-esteem, stressful life events, and a history of trauma or substance abuse. However, in a cancer setting, many patients do not tell their oncologists that they are depressed. They do not want to distract the doctor, they do not want any more medication, or they feel an additional sense of stigma related to depression." Dr. Massie emphasized "While symptoms of depression may overlap with symptoms of the cancer, it is very important for oncologists to use screening tools for depression and to tell their patients that there is help”.
     Viola Vaccarino, MD., PhD., Professor of Medicine at Emory School of Medicine Division of Cardiology, focused on the social and behavioral determinates of cardiovascular disease in women. Depression is more prevalent in heart patients than in the general population, especially in young women with acute heart disease. While many studies have been done showing that depression is significantly related to cardiovascular disease, the multiple pathways of disease affected by depression, such as inflammation, are still being studied. Importantly, genetic medicine is playing a significant role in determining the genetic risk factors that are sex specific in heart disease. Dr. Vaccarino told those attending the ORWH Women's Health Seminar "The links between depression and cardiovascular disease may be more important for women. Obviously, interventions must be tailored to women's stressors." But Dr. Vaccarino cautioned "However, treating both depression and cardiovascular disease is controversial. No study has shown that treating both conditions results in improved cardiovascular disease; and this is disappointing."
     National Institute of Mental Health (NIMH) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. Sex differences in disease patterns are pervasive in clinical medicine. In trying to understand these sex/gender characteristics, treatments tailored to individuals will be more effective in lessening the disease burden of depression and the many other co-occurring diseases. The Office of Research on Women's Health (ORWH) was established in September 1990 within the Office of the Director at the National Institutes of Health (NIH) to serve as a focal point for women's health research.
Goldstein, Jill M. Depression: Examining the Sex/Gender Differences and Links to Other Diseases. The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) Women’s Health Seminar Series. September 10, 2010.
http://www.nimh.nih.gov/health/topics/depression/depression-examining-the-sex-gender-differences-and-links-to-other-diseases.shtml, accessed June 7, 2011. Permanent link: http://videocast.nih.gov/launch.asp?15276
Web Hosting Companies